Medidata announced the launch of Sensor Cloud, a transformative platform for managing a broad range of sensor and digital health technology data during the clinical trial process. Sensor Cloud seamlessly integrates with Medidata Rave Clinical CloudTM and supports continuous patient data collection from both Medidata and third-party medical-grade sensors. This innovation will provide a broader and deeper view into the patient experience. Following Medidata’s recent acquisition of digital biomarker business MC10, the launch of Sensor Cloud further strengthens the company’s unique data ingestion, analytics and insights capabilities that currently provide differentiated value to patients, trial sites, trial sponsors and contract research organizations (CROs). Using Sensor Cloud, researchers can access sensor data through a single Application Programming Interface and integrate new sensor technologies in weeks rather than months. Sensor Cloud provides the ability to: Enable greater insights through proprietary analytics including novel digital biomarker discovery; Lower costs and enable greater operational efficiency by making it easier for patients to share data and stay enrolled in trials; Standardize data from ingestion through delivery via a common data model; and Reduce site and patient burden by cutting down on-site visits, time, and travel through a more flexible engagement model. In 2021, Medidata will continue to expand on its growing list of supported devices and sensors that includes BioStamp?, ActiGraph, and BioIntellisenseTM. This growing library of high fidelity connected devices in combination with Sensor Cloud's analytics will advance researchers' understanding of disease progression and treatment effects in the home, while enhancing the clinical trial experience for patients.